This information was published on 2025-07-17T02:41:48 for IP Right Filed Published.
Field | Value |
(210) | 2567563 (IR 1864185) |
(220) |
29 May 2025
|
(300) |
US, 29 Jan 2025, 99021870
|
(500) |
The mark consists of four lines with curved top and bottom edges that become progressively larger from left to right and form the overall shape of a conical seashell, positioned above the word CRENESSITY.
|
(511) (510) |
Class 5
Pharmaceutical preparations for the treatment of adrenal insufficiency; pharmaceutical preparations for the treatment of hormonal and genetic diseases, disorders and conditions; pharmaceutical preparations for the diagnosis, prevention and treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia; pharmaceuticals for the treatment of rare and orphan hormonal and genetic diseases, disorders and conditions. Class 42 Providing medical research information; providing medical research information in the field of pharmaceuticals and clinical trials focusing on congenital adrenal hyperplasia and other endocrine diseases and disorders; scientific research in the nature of conducting clinical trials for pharmaceutical preparations for the treatment of congenital adrenal hyperplasia and other endocrine diseases and disorders, for others; conducting post-authorization pharmaceutical research for the marketing of pharmaceutical preparations and evaluating epidemiological results. Class 44 Providing medical information; providing medical information to patients, medical professionals, and insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders; on-line information services, namely, providing medical information to patients, medical professionals, and insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders. |
(540) |
|
(550) | Figurative |
(730) |
Neurocrine Biosciences, Inc.
|
Find out more about publications on the About page.